MedTrace Logo

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

NCT03295227 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-01-30

No results posted yet for this study

Summary

This phase I trial studies the sides effects and best dose of pembrolizumab in treating participants with thymoma or thymic cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Stage III Thymoma AJCC v8
  • Stage IIIA Thymoma AJCC v8
  • Stage IIIB Thymoma AJCC v8
  • Stage IV Thymoma AJCC v8
  • Stage IVA Thymoma AJCC v8
  • Stage IVB Thymoma AJCC v8
  • Unresectable Thymic Carcinoma

Interventions

BIOLOGICAL

Pembrolizumab

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Anne S Tsao · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-06
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03295227 on ClinicalTrials.gov